Neuroprotective Effect of Butylphthalide Injection on Patients With Return of Spontaneous Circulation After Cardiac Arrest:a Multicenter, Randomized Clinical Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Cardiac arrest is one of the critical illnesses that is directly life-threatening, and patients who survive cardiac arrest develop severe neurological deficits or even die. The effectiveness of drugs to improve neurological function in resuscitated brain-injured patients has been a focus of research in the field of resuscitation. Butanephthalein has an ameliorating effect on the damage of central nervous function in patients with acute ischemic stroke, and can promote the improvement of patients' neurological deficits. On this basis, the present study was designed as a multicenter, prospective randomized controlled experiment, with internationally accepted methods for assessing near-term and long-term neurological function, to determine the effectiveness of butalbital in improving neurological function after cardiac arrest, with the aim of searching for new methods and ideas to improve neurological function and prognosis after cardiac arrest.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Age 18-80 years old.

• Glasgow Coma Scale (GCS) scores ≤8 upon admission.

• Return of Spontaneous Circulation (ROSC) ≥30min.

• Signed the informed consent form.

Locations
Other Locations
China
Beijing Chao-Yang Hospital
RECRUITING
Beijing
Contact Information
Primary
Ziren Tang, Ph.D
tangziren1970@163.com
+86 010-85231530
Time Frame
Start Date: 2022-01-01
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 350
Treatments
Experimental: Butylphthalide
Butylphthalide and Sodium Chloride Injection 100ml ivgtt bid 14days
Placebo_comparator: Saline Solution
Saline Solution 100ml ivgtt bid 14days
Related Therapeutic Areas
Sponsors
Leads: Tang Ziren

This content was sourced from clinicaltrials.gov